Metastasis represents the single most significant challenge in human colorectal cancer (CRC) treatment. FasL-mediated immune surveillance by T cells is essential for the control of spontaneous cancer growth and metastasis. However, acquisition of resistance to FasL-induced apoptosis is a hallmark of human cancer, particularly metastatic human cancer. In humans, the Fas protein level is high in normal colon tissues, but is generally lower in the primary CRC, and complete loss of Fas protein is often observed in metastatic CRC. Furthermore, it has been shown that acquisition of resistance to Fas-mediated apoptosis is linked to recurrence and adverse prognosis in human CRC patients. Therefore, targeting resistance to Fas-mediated apoptosis is potentially an effective approach to overcome metastatic CRC resistance to FasL+ cytotoxic T lymphocyte (CTL) to suppress CRC immune evasion and progression. On the other hand, IRF8 plays an essential role in: 1) Fas transcription in tumor cells, 2) suppression of MDSC differentiation, and 3) regulation of CTL differentiation. Cancer is not a disease of tumor cell alone, but rather a disease of the tumor microenvironment, which consists of both tumor cells and immune cells. Therefore, systemic investigation of IRF8 functions in regulation of Fas and GM-CSF expression in tumor cells, and regulation MDSC differentiation and CTL differentiation of the immune system is of significance for understanding the cancer pathogenesis in the immune competent hosts. Our central hypothesis is that H3K9me3-mediated FAS transcriptional silencing is a molecular mechanism underlying metastatic colon carcinoma cell immune evasion and IRF8 functions in host tumor rejection through regulating MDSC and CTL differentiation. We propose to test our central hypothesis by pursuing the following 3 specific aims: 1. test the hypothesis that H3K9me3 interferes with interaction between IRF8 and the FAS promoter to represses FAS transcription in metastatic human colon carcinoma cells; 2. test the hypothesis that IRF8 represses GM-CSF expression in tumor cells to mediate tumor-induced MDSC differentiation in vivo; 3. determine the functions of IRF8 in host immune cell-mediated tumor rejection. Successful completion of these proposed studies has the potential to identify molecular targets to enhance the efficacy of CTL cancer immunotherapy to suppress metastatic colorectal cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA133085-07
Application #
9102985
Study Section
Transplantation, Tolerance, and Tumor Immunology (TTT)
Program Officer
Jhappan, Chamelli
Project Start
2008-05-01
Project End
2020-06-30
Budget Start
2016-07-01
Budget End
2017-06-30
Support Year
7
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Georgia Regents University
Department
Biochemistry
Type
Schools of Medicine
DUNS #
City
Augusta
State
GA
Country
United States
Zip Code
30912
Habtetsion, Tsadik; Ding, Zhi-Chun; Pi, Wenhu et al. (2018) Alteration of Tumor Metabolism by CD4+ T Cells Leads to TNF-?-Dependent Intensification of Oxidative Stress and Tumor Cell Death. Cell Metab 28:228-242.e6
Ibrahim, Mohammed L; Klement, John D; Lu, Chunwan et al. (2018) Myeloid-Derived Suppressor Cells Produce IL-10 to Elicit DNMT3b-Dependent IRF8 Silencing to Promote Colitis-Associated Colon Tumorigenesis. Cell Rep 25:3036-3046.e6
Liu, Kebin; Lu, Chunwan (2018) Gut microbes modulate host response to immune checkpoint inhibitor cancer immunotherapy. Transl Cancer Res 7:S608-S610
Lu, Chunwan; Yang, Dafeng; Sabbatini, Maria E et al. (2018) Contrasting roles of H3K4me3 and H3K9me3 in regulation of apoptosis and gemcitabine resistance in human pancreatic cancer cells. BMC Cancer 18:149
Xiao, Wei; Klement, John D; Lu, Chunwan et al. (2018) IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells. J Immunol 201:264-277
Xiao, Wei; Ibrahim, Mohammed L; Redd, Priscilla S et al. (2018) Loss of Fas Expression and Function is Coupled with Colon Cancer Resistance to Immune Checkpoint Inhibitor Immunotherapy. Mol Cancer Res :
Jordan, Andre R; Lokeshwar, Soum D; Lopez, Luis E et al. (2017) Antitumor activity of sulfated hyaluronic acid fragments in pre-clinical models of bladder cancer. Oncotarget 8:24262-24274
Lu, Chunwan; Liu, Kebin (2017) Epigenetic regulation of PD-L1 expression and pancreatic cancer response to checkpoint immunotherapy. Transl Cancer Res 6:S652-S654
Redd, Priscilla S; Ibrahim, Mohammed L; Klement, John D et al. (2017) SETD1B Activates iNOS Expression in Myeloid-Derived Suppressor Cells. Cancer Res 77:2834-2843
Lu, Chunwan; Talukder, Asif; Savage, Natasha M et al. (2017) JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer. Oncoimmunology 6:e1291106

Showing the most recent 10 out of 58 publications